Results 211 to 220 of about 19,945,001 (395)

Cystatin C quantification in CSF. [PDF]

Clinical Chemistry, 1989
J M Sheat, Peter M. George
openaire   +3 more sources

Effect of creatine monohydrate on motor function in children with facioscapulohumeral muscular dystrophy: A multicenter, randomized, double‐blind placebo‐controlled crossover trial

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView.
Abstract Background Facioscapulohumeral muscular dystrophy (FSHD) is a rare, progressive muscle disease with no available disease‐modifying therapy. Creatine monohydrate (CrM) has been shown to improve muscle strength in individuals with muscular dystrophies but has not been tested in young people with FSHD.
Ian R. Woodcock, Katy de Valle, Anita Cairns, Zoe E. Davidson, Michael Kean, Nisha Varma, Anneke Grobler, David Metz, Kate Carroll, Nuran Dilek, Chad Heatwole, Monique M. Ryan, Martin B. Delatycki, Eppie M. Yiu   +13 more
wiley   +1 more source

Does adjustment of GFR to extracellular fluid volume improve the clinical utility of cystatin C? [PDF]

, 2000
Eric S Kilpatrick
openalex   +1 more source

The Omics‐Driven Machine Learning Path to Cost‐Effective Precision Medicine in Chronic Kidney Disease

PROTEOMICS, EarlyView.
ABSTRACT Chronic kidney disease (CKD) poses a significant and growing global health challenge, making early detection and slowing disease progression essential for improving patient outcomes. Traditional diagnostic methods such as glomerular filtration rate and proteinuria are insufficient to capture the complexity of CKD.
Marta B. Lopes, Roberta Coletti, Flore Duranton, Griet Glorieux, Mayra Alejandra Jaimes Campos, Julie Klein, Matthias Ley, Paul Perco, Alexia Sampri, Aviad Tur‐Sinai   +9 more
wiley   +1 more source

Serum cystatin C and chemerin levels in diabetic retinopathy [PDF]

, 2017
Peer reviewedPublisher ...
Chen, Xuedong, Li, Qingjun, Yu, Tian, Yu, Yongbin, Zhang, Liqiong, Zhao, Shiyong   +5 more
core  

Editorial Comment on “Zinner Syndrome Presenting With Chronic Pelvic Pain and Ejaculatory Dysfunction” From Dr. Sourav and Dr. Tweheyo

IJU Case Reports, EarlyView.
Sourav Sudan, Tweheyo Ronald
wiley   +1 more source

A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 5, Page 891-903, May 2025.
ABSTRACT Duchenne muscular dystrophy (DMD) is characterized by progressive, irreversible muscle damage that usually leads to premature death from cardiac or respiratory failure. Eteplirsen is a phosphorodiamidate morpholino oligomer and the first antisense oligonucleotide (ASO) approved for the treatment of patients with exon 51 skip‐amenable DMD. This
Yogesh Patel, Larry Orogun, Nicole Yocum, Louise R. Rodino‐Klapac, Lilly East   +4 more
wiley   +1 more source

Cystatin C measurement: Improved detection of mild decrements in glomerular filtration rate versus creatinine-based estimates? [PDF]

, 2000
Andrew G. Bostom, Lance D. Dworkin
openalex   +1 more source

The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease based on a multicenter retrospective cohort study

VIEW, EarlyView.
A retrospective, multicenter cohort study was conducted across nine hospitals in Henan Province, aiming to evaluate the efficacy and safety of azvudine in hospitalized COVID‐19 patients with kidney disease. Through the application of Kaplan‒Meier and multivariate Cox regression analyses, it was found that azvudine may have potential effects in reducing
Bo Yu, Mengzhao Yang, Jia Yu, Daming Wang, Hong Luo, Ming Cheng, Shixi Zhang, Guotao Li, Ling Wang, Guowu Qian, Donghua Zhang, Silin Li, Zhigang Ren, Quancheng Kan   +13 more
wiley   +1 more source

Domain-swapping dimerization of human cystatin C [PDF]

, 2000
Mariusz Jaskólski, Robert Janowski, Maciej Kozak, Elżbieta Jankowska, Zbigniew Grzonka, Anders Grubb, M. Alvarez Fernandez, Magnus Abrahamson   +7 more
openalex   +1 more source